Metallothionein as a spinocellular tumour biomarker: analysis
of tumorous tissue samples

a 2013

Metallothionein as a spinocellular tumour biomarker: analysis of tumorous tissue samples

GUMULEC, Jaromír, Markéta SZTALMACHOVÁ, Hana POLANSKÁ, Monika HOLUBOVÁ, Jan BALVAN et. al.

Basic information

Original name

Metallothionein as a spinocellular tumour biomarker: analysis of tumorous tissue samples

Authors

Edition

The 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine, 2013

Other information

Type of outcome

Konferenční abstrakt

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.880

ISSN

UT WoS

000324507400173

Změněno: 9/1/2014 10:14, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Over 40,000 new cases of head and neck tumours are diagnosed in United States every year (1), thus, these tumours are an important issue, in male population, in particular. Histologically, tumours of head and neck comprise relatively uniform group of mostly spinocellular tumours with unique zinc and zinc-binding protein metallothionein (MT) metabolism (2). In these tumours, elevated levels of both zinc (II) and MT were observed by numerous studies. Therefore, a potential use of those substances as tumour markers was outlined. Thus, the aim of this pilot study was to analyse the level of MT in tissue first obtained samples of histologically verified spinocellular tumours using electrochemical detection. The MT levels were compared with levels in adjacent tissues and correlated with TNM staging. Total 30 tissue samples were collected and analysed due 2013 with following locations included: oral cavity and pharynx. Significantly higher (t-test, p < 0.05) MT content was determined in both locations compared to adjacent tissue. In contrast, no significant differences were determined between oral cavity and pharyngeal tumours. With regard to tumour staging, significant positive correlation was determined (r = 0.79, p < 0.05). These preliminary results indicate MT as an important molecule in the head and neck tumour development and a potential diagnostic biomarker for this tumor type, however further studies on increasing number of samples will provide more detailed conclusions. References: 1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. Ca-a Cancer Journal for Clinicians 63: 11-30, 2013. 2. Eckschlager T, Adam V, Hrabeta J, Figova K and Kizek R: Metallothioneins and Cancer. Curr Protein Pept Sci 10: 360-375, 2009.

Links

NT14337, research and development project

Name: Studium a charakterizace primárních nádorových buněčných linií spinocelulárních karcinomů v oblasti hlavy a krku a jejich maligní potenciál.

Investor: Ministry of Health of the CR

Citovat

GUMULEC, Jaromír, Markéta SZTALMACHOVÁ, Hana POLANSKÁ, Monika HOLUBOVÁ, Jan BALVAN, Hana BINKOVÁ, Zuzana HORÁKOVÁ, Rom KOSTŘICA, Ondřej ZÍTKA, Vojtěch ADAM, René KIZEK and Michal MASAŘÍK. Metallothionein as a spinocellular tumour biomarker: analysis of tumorous tissue samples. In The 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine. 2013. ISSN 1107-3756.

@proceedings{1136285,
   author = {Gumulec, Jaromír and Sztalmachová, Markéta and Polanská, Hana and Holubová, Monika and Balvan, Jan and Binková, Hana and Horáková, Zuzana and Kostřica, Rom and Zítka, Ondřej and Adam, Vojtěch and Kizek, René and Masařík, Michal},
   booktitle = {The 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine},
   title = {Metallothionein as a spinocellular tumour biomarker: analysis of tumorous tissue samples},
   year = {2013}
}

TY  - CONF
ID  - 1136285
AU  - Gumulec, Jaromír - Sztalmachová, Markéta - Polanská, Hana - Holubová, Monika - Balvan, Jan - Binková, Hana - Horáková, Zuzana - Kostřica, Rom - Zítka, Ondřej - Adam, Vojtěch - Kizek, René - Masařík, Michal
PY  - 2013
TI  - Metallothionein as a spinocellular tumour biomarker: analysis of tumorous tissue samples
N2  - Over 40,000 new cases of head and neck tumours are diagnosed in United States every year (1), thus, these tumours are an important issue, in male population, in particular. Histologically, tumours of head and neck comprise relatively uniform group of mostly spinocellular tumours with unique zinc and zinc-binding protein metallothionein (MT) metabolism (2). In these tumours, elevated levels of both zinc (II) and MT were observed by numerous studies. Therefore, a potential use of those substances as tumour markers was outlined. Thus, the aim of this pilot study was to analyse the level of MT in tissue first obtained samples of histologically verified spinocellular tumours using electrochemical detection. The MT levels were compared with levels in adjacent tissues and correlated with TNM staging. Total 30 tissue samples were collected and analysed due 2013 with following locations included: oral cavity and pharynx. Significantly higher (t-test, p < 0.05) MT content was determined in both locations compared to adjacent tissue. In contrast, no significant differences were determined between oral cavity and pharyngeal tumours. With regard to tumour staging, significant positive correlation was determined (r = 0.79, p < 0.05). These preliminary results indicate MT as an important molecule in the head and neck tumour development and a potential diagnostic biomarker for this tumor type, however further studies on increasing number of samples will provide more detailed conclusions. References: 1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. Ca-a Cancer Journal for Clinicians 63: 11-30, 2013. 2. Eckschlager T, Adam V, Hrabeta J, Figova K and Kizek R: Metallothioneins and Cancer. Curr Protein Pept Sci 10: 360-375, 2009.
ER  -

GUMULEC, Jaromír, Markéta SZTALMACHOVÁ, Hana POLANSKÁ, Monika HOLUBOVÁ, Jan BALVAN, Hana BINKOVÁ, Zuzana HORÁKOVÁ, Rom KOSTŘICA, Ondřej ZÍTKA, Vojtěch ADAM, René KIZEK and Michal MASAŘÍK. Metallothionein as a spinocellular tumour biomarker: analysis of tumorous tissue samples. In \textit{The 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine}. 2013. ISSN~1107-3756.

Detailed Information on Publication Record